Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

NCT07796646 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.

NCT NCT07796646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07796646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Lead sponsor
Laboratoires Thea
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 5, 2026
Completion date
March 31, 2030
Enrollment
81 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

deaf blind, eye diseases, hereditary, eye disorders congenital, retinal disease, retinitis pigmentosa (rp), usher syndrome type 2, vision disorders